← All trials
NCT04263337
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2020
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Feb 10, 2020
- Last posted
- Dec 7, 2022
- Enrollment
- 250
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Medical College of WisconsinCollaborator
- Medical College of WisconsinOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- Harvard UniversityOfficial
- University of North Carolina at Chapel HillOfficial
- Medical College of WisconsinOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.